Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Laekna, Inc. ( (HK:2105) ).
Laekna, Inc. has announced the submission of an Investigational New Drug amendment to the U.S. FDA for its obesity treatment drug, LAE102. This development follows an IND approval in April 2024 and a clinical collaboration with Eli Lilly to accelerate global clinical trials. The U.S. Phase 1 Clinical Trial is set to begin in the second quarter of 2025, with Eli Lilly responsible for execution and funding. LAE102 has shown promise in pre-clinical models for increasing lean mass and reducing fat mass, positioning it as a potential novel treatment for obesity.
More about Laekna, Inc.
Laekna, Inc. is a company incorporated in the Cayman Islands, operating in the pharmaceutical industry. It focuses on developing precision therapies, with a particular emphasis on treatments for obesity. The company’s primary product in this area is LAE102, a monoclonal antibody targeting ActRIIA, involved in muscle regeneration and lipid metabolism.
YTD Price Performance: 55.18%
Average Trading Volume: 6,974,458
Technical Sentiment Signal: Strong Sell
Find detailed analytics on 2105 stock on TipRanks’ Stock Analysis page.